Stamulumab (MYO-029
[Wyeth Product Pipeline](_blank)
Wyeth
Wyeth, LLC was an American pharmaceutical company. The company was founded in Philadelphia, Pennsylvania, in 1860 as ''John Wyeth and Brother''. It was later known, in the early 1930s, as American Home Products, before being renamed to Wyeth in ...
, Website accessed April 22, 2007) is an experimental
myostatin
Myostatin (also known as growth differentiation factor 8, abbreviated GDF8) is a protein that in humans is encoded by the ''MSTN'' gene. Myostatin is a myokine that is produced and released by myocytes and acts on muscle cells to inhibit muscle ...
inhibiting drug developed by
Wyeth Pharmaceuticals
Wyeth, LLC was an American pharmaceutical company. The company was founded in Philadelphia, Pennsylvania, in 1860 as ''John Wyeth and Brother''. It was later known, in the early 1930s, as American Home Products, before being renamed to Wyeth in ...
for the treatment of
muscular dystrophy
Muscular dystrophies (MD) are a genetically and clinically heterogeneous group of rare neuromuscular diseases that cause progressive weakness and breakdown of skeletal muscles over time. The disorders differ as to which muscles are primarily affe ...
(MD). Stamulumab was formulated and tested by Wyeth in
Collegeville, Pennsylvania
Collegeville is a borough in Montgomery County, Pennsylvania, a suburb outside of Philadelphia on Perkiomen Creek. Collegeville was incorporated in 1896. It is the location of Ursinus College which opened in 1869. The population was 5,089 at t ...
.
NIH
The National Institutes of Health, commonly referred to as NIH (with each letter pronounced individually), is the primary agency of the United States government responsible for biomedical and public health research. It was founded in the late ...
's ClinicalTrials.gov
ClinicalTrials.gov is a registry of clinical trials. It is run by the United States National Library of Medicine (NLM) at the National Institutes of Health, and is the largest clinical trials database, holding registrations from over 329,000 tri ...
Study Evaluating MYO-029 in Adult Muscular Dystrophy
record last updated January 24, 2007 Myostatin is a
protein
Proteins are large biomolecules and macromolecules that comprise one or more long chains of amino acid residues. Proteins perform a vast array of functions within organisms, including catalysing metabolic reactions, DNA replication, respo ...
that inhibits the growth of muscle tissue, stamulumab is a
recombinant human
antibody
An antibody (Ab), also known as an immunoglobulin (Ig), is a large, Y-shaped protein used by the immune system to identify and neutralize foreign objects such as pathogenic bacteria and viruses. The antibody recognizes a unique molecule of the ...
designed to bind to and inhibit the activity of myostatin.
Stamulumab is a
G1 immunoglobulin
An antibody (Ab), also known as an immunoglobulin (Ig), is a large, Y-shaped protein used by the immune system to identify and neutralize foreign objects such as pathogenic bacteria and viruses. The antibody recognizes a unique molecule of the ...
antibody which binds to myostatin and prevents it from binding to its target site, thus inhibiting the growth-limiting action of myostatin on muscle tissue. Research completed in 2002 found that Stamulumab might one day prove to be an effective treatment for
Duchenne muscular dystrophy
Duchenne muscular dystrophy (DMD) is a severe type of muscular dystrophy that primarily affects boys. Muscle weakness usually begins around the age of four, and worsens quickly. Muscle loss typically occurs first in the thighs and pelvis fol ...
.
[Blocking Myostatin Proves Beneficial in Mice with DMD](_blank)
MDA Research News, 27 November 2002
Phase 1 and 2 trials
Wyeth undertook a Phase 1 and 2
clinical trial
Clinical trials are prospective biomedical or behavioral research studies on human participants designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietar ...
in 2005 and 2006 of stamulumab. The multiple ascending dose trial (36 patients per
cohort
Cohort or cohortes may refer to:
* Cohort (educational group), a group of students working together through the same academic curriculum
* Cohort (floating point), a set of different encodings of the same numerical value
* Cohort (military unit ...
) contained some measures of efficacy. The trial's participants included people afflicted with
Facioscapulohumeral muscular dystrophy
Facioscapulohumeral muscular dystrophy (FSHD) is a type of muscular dystrophy, a group of heritable diseases that cause degeneration of muscle and progressive weakness. Per the name, FSHD tends to sequentially weaken the muscles of the face, ...
,
Becker's muscular dystrophy
Becker muscular dystrophy is an X-linked recessive inherited disorder characterized by slowly progressing muscle weakness of the legs and pelvis. It is a type of dystrophinopathy. This is caused by mutations in the dystrophin gene, which encodes ...
, and
Limb-girdle muscular dystrophy. Through 2007 Wyeth had been analyzing the results but the hoped-for news and/or a publication in 2007 did not occur.
[Wyeth Analyzing MYO-029 Results](_blank)
Muscular Dystrophy Association
The Muscular Dystrophy Association (MDA) is an American 501(c)(3) umbrella organization that works to support people with neuromuscular diseases. Founded in 1950 by Paul Cohen, who lived with muscular dystrophy, it works to combat neuromuscular di ...
announcement, December 4, 2006[FSH Watch Newsletter](_blank)
pg 11, FSH Society, Summer 2007 On January 24, 2008, Wyeth announced that the study had been accepted by a peer-reviewed journal and publication was expected "in the next few months".
[Pharma Company Responds to WiSci on Muscle-Building Drug](_blank)
Wired Science, Alexis Madrigal
Alexis Madrigal (born 1983/84) is an American journalist. He's currently the new co-host of KQED's Forum.
In 2010, Madrigal began working for ''The Atlantic''. In 2014, he was promoted to deputy editor of TheAtlantic.com. He joined ''Fusion'' la ...
, January 24, 2008, 2008, 4:26:27 PM The publication appeared in
Annals of Neurology
''Annals of Neurology'' is a peer-reviewed medical journal publishing articles of "broad interest in neurology, particularly those with high impact in understanding the mechanisms and treatment of diseases of the human nervous system." The journal ...
in May 2008.
On 11 March 2008, it was announced that Wyeth would not develop the drug further for MD, but would continue to explore myostatin inhibition along with other strategies.
Wyeth Won't Develop MYO-029 for MD
/ref>
See also
* ACVR2B
Activin receptor type-2B is a protein that in humans is encoded by the ''ACVR2B'' gene. ACVR2B is an activin type 2 receptor.
Function
Activins are dimeric growth and differentiation factors which belong to the transforming growth factor-be ...
represents an alternative approach to inhibiting myostatin. Not belonging to the antibody class of molecules, the ACVR2B protein drug is rather mimicking myostatin's endogenous binding partner, therefore competing for its binding affinity.[New Myostatin Blocker Makes Mouse Muscles 60 Percent Larger](_blank)
MDA
MDA, mda, or ''variation'', may refer to:
Places
* Moldova, a country in Europe with the ISO 3166-1 country code MDA Politics
* Meghalaya Democratic Alliance (2018), ruling coalition government in the Indian State of Meghalaya led by National Pe ...
Research News, January 6, 2006
References
{{TGFβ receptor superfamily modulators
Wyeth brands
Abandoned drugs
Monoclonal antibodies
Myostatin inhibitors